drugset
drugset / Trial / NCT06766578

Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06766578 ↗

Phase 2 Recruiting 32 enrolled Shandong Provincial Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the initial efficacy and safety of neoadjuvant low-dose interval radiotherapy combined with tirelizumab and SOX chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma.

Timeline

Start
2024-12-30
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous
Subject S-1 Small molecule 40 mg/m2 Oral
Subject Tirelizumab Monoclonal antibody 200 mg Intravenous

Indications

adenocarcinoma